Last updated on May 2019

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)


Brief description of study

Primary Objective:

  • To demonstrate that sotagliflozin reduces cardiovascular (CV) mortality and morbidity (composite of CV death or hospitalization for heart failure [HHF]) compared to placebo in hemodynamically stable patients with type 2 diabetes (T2D) and heart failure (HF) with left ventricular ejection fraction (LVEF) <50%, after admission for worsening heart failure (WHF).
  • To demonstrate that sotagliflozin reduces cardiovascular (CV) mortality and morbidity (composite of CV death or hospitalization for heart failure [HHF]) compared to placebo in hemodynamically stable patients with T2D and HF irrespective of LVEF after admission for WHF.

Secondary Objectives:

  • To demonstrate that, when compared to placebo in the toal patient population, sotagliflozin reduces the total number (i.e., including recurrent events) of the following clinical events:
  • Cardiovascular death, HHF or urgent HF visit.
  • To demonstrate that, when compared to placebo, sotagliflozin reduces:
  • The composite of positively adjudicated sustained 50% decrease in eGFR, chronic dialysis, renal transplant or positively adjudicated sustained eGFR <15 mL/min/1.73 m2 in the total patient population.
  • Cardiovascular death in patients with LVEF < 50%.
  • Cardiovascular death in the total patient population.
  • All-cause mortality in patients with LVEF < 50%.
  • All cause mortality in the total patient population.
  • To demonstrate the safety and tolerability of sotagliflozin in the total population in this study.

Detailed Study Description

The estimated study duration for a given patient will be approximately 3 to 32 months.

Clinical Study Identifier: NCT03521934

Find a site near you

Start Over

Investigational Site Number 8400007

Redondo Beach, CA United States
  Connect »

Investigational Site Number 8400057

Port Charlotte, FL United States
  Connect »

Investigational Site Number 8400067

Arlington Heights, IL United States
  Connect »

Investigational Site Number 8400014

Oklahoma City, OK United States
  Connect »

Investigational Site Number 0320002

Ciudad De Buenos Aires, Argentina
  Connect »

Investigational Site Number 0320028

San Miguel De Tucuman, Argentina
  Connect »

Investigational Site Number 0320019

San Miguel De Tucuman, Argentina
  Connect »

Investigational Site Number 2760011

Rotenburg An Der Fulda, Germany
  Connect »

Investigational Site Number 4100001

Hwaseong-Si, Korea, Republic of
  Connect »

Investigational Site Number 4100005

Seongnam-Si, Korea, Republic of
  Connect »

Investigational Site Number 6430018

Nizhniy Novgorod, Russian Federation
  Connect »

Investigational Site Number 6430013

Rostov-Na-Donu, Russian Federation
  Connect »

Investigational Site Number 6430011

Saint-Petersburg, Russian Federation
  Connect »

Investigational Site Number 6430007

St-Petersburg, Russian Federation
  Connect »

Investigational Site Number 6430012

St-Petersburg, Russian Federation
  Connect »

Investigational Site Number 6430009

St-Petersburg, Russian Federation
  Connect »

Investigational Site Number 7240005

Las Palmas De Gran Canaria, Spain
  Connect »

Investigational Site Number 7240009

San Sebastián De Los Reyes, Spain
  Connect »

Investigational Site Number 7240009

San Sebastián De Los Reyes, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.